On November 10, 2016, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock abbreviation: Fosun Pharmaceutical; stock code: 600196.SH, 02196.HK, hereinafter as “Fosun Pharmaceutical”) completed all works in the offering stage of its private placement of A shares. The CSRC approval (Approval regarding the Private Placement of Shares of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) for this private placement was obtained on June 3, 2016, which will non-publicly offer no more than 100,436,681 A shares and raise an amount of RMB 2,299,999,994.90 that would be mainly used for repayment of its interest-bearing debts.

Fosun Pharmaceutical, founded in 1994, was listed on the main board of Shanghai Stock Exchange and Hong Kong Stock Exchange respectively on August 1998 and October 2012. It is a leading listed company in pharmaceutical sector in China. Fosun Pharmaceutical strategically covers many important links of the medical health industry chain, from R&D, medicine manufacturing, medical diagnosis and medical equipment to pharmaceutical distribution and retail and medical services. Fosun Pharmaceutical has national enterprise technical center and international R&D team which focus on the treatment of cardiovascular system, anti-tumor, central nervous system, blood system, metabolism and digestive system and anti-infection, and its main products are all among the top of their respective niche markets.

AllBright team consists of senior partners ZHU Linhai and BAO Fangzhou, partner QUE Lina, and associates CHEN Wei, Lou Chunhan, JIANG Lulu and DONG Qiuyan accepted the joint engagement of UBS Securities Co. Limited and Tebon Securities Co., Ltd. and provided all-sided legal services as securities trader lawyers for the 2015 private placement of A Shares by Fosun Pharmaceutical.